BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother. 2013;62:919-929. [PMID: 23197273 DOI: 10.1007/s00262-012-1379-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Mukherjee AG, Wanjari UR, Prabakaran DS, Ganesan R, Renu K, Dey A, Vellingiri B, Kandasamy S, Ramesh T, Gopalakrishnan AV. The Cellular and Molecular Immunotherapy in Prostate Cancer. Vaccines (Basel) 2022;10:1370. [PMID: 36016257 DOI: 10.3390/vaccines10081370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Jiang C, Li J, Zhang W, Zhuang Z, Liu G, Hong W, Li B, Zhang X, Chao C. Potential association factors for developing effective peptide-based cancer vaccines. Front Immunol 2022;13:931612. [DOI: 10.3389/fimmu.2022.931612] [Reference Citation Analysis]
3 DeLucia DC, Lee JK. Development of Cancer Immunotherapies. Cancer Treat Res 2022;183:1-48. [PMID: 35551655 DOI: 10.1007/978-3-030-96376-7_1] [Reference Citation Analysis]
4 Liu T, Tan J, Wu M, Fan W, Wei J, Zhu B, Guo J, Wang S, Zhou P, Zhang H, Shi L, Li J. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells. Gut 2021;70:1965-77. [PMID: 33262196 DOI: 10.1136/gutjnl-2020-322196] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
5 Zhang W, Yin Q, Huang H, Lu J, Qin H, Chen S, Zhang W, Su X, Sun W, Dong Y, Li Q. Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021;11:628456. [PMID: 33928024 DOI: 10.3389/fonc.2021.628456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Al-Rajabi R, Sun W. Immunotherapy in cholangiocarcinoma. Curr Opin Gastroenterol 2021;37:105-11. [PMID: 33507028 DOI: 10.1097/MOG.0000000000000715] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Lin D, He H, Sun J, He X, Long W, Cui X, Sun Y, Zhao S, Zheng X, Zeng Z, Zhang K, Wang H. Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses. Vaccine 2021;39:1609-20. [PMID: 33612342 DOI: 10.1016/j.vaccine.2021.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Michiyuki S, Tomita N, Mori Y, Kanda H, Tashiro K, Notomi T. Discrimination of a single nucleotide polymorphism in the haptoglobin promoter region, rs5472, using a competitive fluorophore-labeled probe hybridization assay following loop-mediated isothermal amplification. Biosci Biotechnol Biochem 2021;85:359-68. [PMID: 33604636 DOI: 10.1093/bbb/zbaa012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bansal D, Reimers MA, Knoche EM, Pachynski RK. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2021;13:334. [PMID: 33477569 DOI: 10.3390/cancers13020334] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
10 Kumar C, Singh RP, Dwiwedi MK, Amit A. Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential. Colon Cancer Diagnosis and Therapy 2021. [DOI: 10.1007/978-3-030-63369-1_14] [Reference Citation Analysis]
11 Uchino Y, Muroya D, Yoshitomi M, Shichijo S, Yamada A, Sasada T, Yamada T, Okuda K, Itoh K, Yutani S. Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer. Mol Clin Oncol 2021;14:39. [PMID: 33437477 DOI: 10.3892/mco.2020.2201] [Reference Citation Analysis]
12 Suekane S, Yutani S, Yamada A, Sasada T, Matsueda S, Takamori S, Toh U, Kawano K, Yoshiyama K, Sakamoto S, Sugawara S, Komatsu N, Yamada T, Naito M, Terasaki M, Mine T, Itoh K, Shichijo S, Noguchi M. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients. Int J Oncol 2020;56:1479-89. [PMID: 32236612 DOI: 10.3892/ijo.2020.5019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Sanjari-moghaddam A, Sadeghi F, Soleyman-jahi S. Immunotherapy of Gastric and Esophageal Cancers. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_8] [Reference Citation Analysis]
14 Dracopoli NC, Grewal I, Takimoto CH, Lebowitz PF. Personalized Medicine in Oncology Drug Development. Holland‐Frei Cancer Medicine 2019. [DOI: 10.1002/9781119000822.hfcm052.pub2] [Reference Citation Analysis]
15 Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD. Past, Current, and Future of Immunotherapies for Prostate Cancer.Front Oncol. 2019;9:884. [PMID: 31572678 DOI: 10.3389/fonc.2019.00884] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 14.3] [Reference Citation Analysis]
16 Nakahara Y, Kouro T, Igarashi Y, Kawahara M, Sasada T. Prospects for a personalized peptide vaccine against lung cancer. Expert Review of Vaccines 2019;18:703-9. [DOI: 10.1080/14760584.2019.1635461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
17 Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y, Liu Q, Wang Q, Sun Z, Zhou S, Du S, Wei J, Liu B. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest 2019;129:2056-70. [PMID: 30835255 DOI: 10.1172/JCI99538] [Cited by in Crossref: 87] [Cited by in F6Publishing: 96] [Article Influence: 21.8] [Reference Citation Analysis]
18 Noguchi M, Koga N, Moriya F, Suekane S, Yutani S, Yamada A, Shichijo S, Kakuma T, Itoh K. Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers. Cancer Sci 2018;109:2660-9. [PMID: 29938870 DOI: 10.1111/cas.13709] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
19 Guan X, Chen J, Hu Y, Lin L, Sun P, Tian H, Chen X. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase. Biomaterials 2018;171:198-206. [PMID: 29698869 DOI: 10.1016/j.biomaterials.2018.04.039] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 14.4] [Reference Citation Analysis]
20 Shah UA, Nandikolla AG, Rajdev L. Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol 2017;18:44. [PMID: 28660602 DOI: 10.1007/s11864-017-0486-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
21 Wada S, Yada E, Ohtake J, Sasada T. Personalized peptide vaccines for cancer therapy: current progress and state of the art. Expert Review of Precision Medicine and Drug Development 2017;2:371-81. [DOI: 10.1080/23808993.2017.1403286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
22 Suekane S, Ueda K, Nishihara K, Sasada T, Yamashita T, Koga N, Yutani S, Shichijo S, Itoh K, Igawa T, Noguchi M. Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. Cancer Sci 2017;108:2430-7. [PMID: 28940789 DOI: 10.1111/cas.13404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
23 Koga N, Moriya F, Waki K, Yamada A, Itoh K, Noguchi M. Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine. Cancer Sci 2017;108:2326-32. [PMID: 28898532 DOI: 10.1111/cas.13397] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
24 Xie J, Yang C, Liu Q, Li J, Liang R, Shen C, Zhang Y, Wang K, Liu L, Shezad K, Sullivan M, Xu Y, Shen G, Tao J, Zhu J, Zhang Z. Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response. Small 2017;13:1701741. [DOI: 10.1002/smll.201701741] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
25 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
26 Anastasopoulou EA, Voutsas IF. Further insight into AE37 peptide vaccination in prostate cancer. Future Science OA 2017;3:FSO192. [DOI: 10.4155/fsoa-2017-0005] [Reference Citation Analysis]
27 Yutani S, Shirahama T, Muroya D, Matsueda S, Yamaguchi R, Morita M, Shichijo S, Yamada A, Sasada T, Itoh K. Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. Cancer Sci. 2017;108:1732-1738. [PMID: 28622427 DOI: 10.1111/cas.13301] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
28 Gowhari Shabgah A, Gholizadeh Navashenaq J, Seyedzadeh MH, Moghadasi SAH, Shokri F, Razavi SA, Kardar GA. Effects of Viral Peptide Presentation on CD4+ T Cell Responses to MHC Class II-Restricted Tumor Peptides. Int J Cancer Manag 2017;10. [DOI: 10.5812/ijcm.8174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Noguchi M, Koga N, Igawa T, Itoh K. Clinical development of immunotherapy for prostate cancer. Int J Urol 2017;24:675-80. [PMID: 28636142 DOI: 10.1111/iju.13397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
30 Yu DP, Cheng X, Liu ZD, Xu SF. Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. Oncol Lett. 2017;14:1568-1580. [PMID: 28789381 DOI: 10.3892/ol.2017.6274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
31 Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Naitou M, Sasada T, Hattori N, Kohno N, Itoh K. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele. Cancer Sci 2017;108:598-603. [PMID: 28178396 DOI: 10.1111/cas.13189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
32 Sakamoto S, Yamada T, Terazaki Y, Yoshiyama K, Sugawara S, Takamori S, Matsueda S, Shichijo S, Yamada A, Noguchi M, Itoh K, Hattori N, Kohno N, Sasada T. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer. Clin Lung Cancer 2017;18:e385-94. [PMID: 28416261 DOI: 10.1016/j.cllc.2017.03.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
33 Loi M, Desideri I, Greto D, Mangoni M, Sottili M, Meattini I, Becherini C, Terziani F, Delli Paoli C, Olmetto E, Bonomo P, Livi L. Radiotherapy in the age of cancer immunology: Current concepts and future developments. Crit Rev Oncol Hematol 2017;112:1-10. [PMID: 28325250 DOI: 10.1016/j.critrevonc.2017.02.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
34 Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. Int Immunopharmacol 2017;44:197-202. [PMID: 28110220 DOI: 10.1016/j.intimp.2017.01.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
35 Yutani S, Itoh K. Personalized Peptide Vaccine for Advanced Pancreatic Cancer. Pancreatic Cancer 2017. [DOI: 10.1007/978-3-662-47181-4_40] [Reference Citation Analysis]
36 Voutsas IF, Anastasopoulou EA, Tzonis P, Papamichail M, Perez SA, Baxevanis CN. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide. J Immunother Cancer 2016;4:75. [PMID: 27891225 DOI: 10.1186/s40425-016-0183-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
37 Sakamoto S, Yutani S, Shichijo S, Morita M, Yamada A, Itoh K, Noguchi M. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site. Cancer Immunol Immunother 2016;65:1223-31. [PMID: 27549314 DOI: 10.1007/s00262-016-1887-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Dammeijer F, Lievense LA, Veerman GD, Hoogsteden HC, Hegmans JP, Arends LR, Aerts JG. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol 2016;34:3204-12. [PMID: 27432922 DOI: 10.1200/JCO.2015.66.3955] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
39 Iwasa S, Yamada Y, Heike Y, Shoji H, Honma Y, Komatsu N, Matsueda S, Yamada A, Morita M, Yamaguchi R, Tanaka N, Kawahara A, Kage M, Shichijo S, Sasada T, Itoh K. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients. Cancer Sci 2016;107:590-600. [PMID: 26920496 DOI: 10.1111/cas.12919] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
40 Silva JM, Préat V, Florindo HF. Aliphatic Polyesters: Particulate Vaccine Delivery. Encyclopedia of Biomedical Polymers and Polymeric Biomaterials 2016. [DOI: 10.1081/e-ebpp-120050384] [Reference Citation Analysis]
41 Gulbake A, Jain A, Jain A, Jain A, Jain SK. Insight to drug delivery aspects for colorectal cancer. World J Gastroenterol 2016; 22(2): 582-599 [PMID: 26811609 DOI: 10.3748/wjg.v22.i2.582] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
42 Chai Y. Immunotherapy of biliary tract cancer. Tumour Biol 2016;37:2817-21. [PMID: 26729196 DOI: 10.1007/s13277-015-4743-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
43 Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother 2016;65:151-60. [PMID: 26728480 DOI: 10.1007/s00262-015-1781-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
44 Noguchi M, Koga N, Moriya F, Itoh K. Immunotherapy in prostate cancer: challenges and opportunities. Immunotherapy 2016;8:69-77. [DOI: 10.2217/imt.15.101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
45 Marks EI, Yee NS. Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. World J Gastrointest Oncol 2015; 7(11): 338-346 [PMID: 26600933 DOI: 10.4251/wjgo.v7.i11.338] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
46 Subhash VV, Yeo MS, Tan WL, Yong WP. Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. J Immunol Res. 2015;2015:308574. [PMID: 26579545 DOI: 10.1155/2015/308574] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
47 Matsueda S, Shichijo S, Nagata S, Seki C, Yamada A, Noguchi M, Itoh K. Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine. Cancer Sci 2015;106:1493-8. [PMID: 26331453 DOI: 10.1111/cas.12805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
48 Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kudo M, Noguchi M. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. J Immunol Res 2015;2015:473909. [PMID: 26539554 DOI: 10.1155/2015/473909] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
49 Araki H, Pang X, Komatsu N, Soejima M, Miyata N, Takaki M, Muta S, Sasada T, Noguchi M, Koda Y, Itoh K, Kuhara S, Tashiro K. Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients. Cancer Immunol Immunother 2015;64:1565-73. [PMID: 26428930 DOI: 10.1007/s00262-015-1756-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
50 Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele. Cancer Sci 2015;106:1257-63. [PMID: 26212219 DOI: 10.1111/cas.12757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
51 Kawano K, Tsuda N, Waki K, Matsueda S, Hata Y, Ushijima K, Itoh K, Yamada A, Kamura T. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy. Cancer Sci 2015;106:1111-7. [PMID: 26122553 DOI: 10.1111/cas.12729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
52 Chen J, Zurawski G, Zurawski S, Wang Z, Akagawa K, Oh S, Hideki U, Fay J, Banchereau J, Song W, Palucka AK. A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40. J Hematol Oncol 2015;8:35. [PMID: 25888530 DOI: 10.1186/s13045-015-0131-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
53 Noguchi M, Arai G, Matsumoto K, Naito S, Moriya F, Suekane S, Komatsu N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. Cancer Immunol Immunother 2015;64:493-505. [PMID: 25662406 DOI: 10.1007/s00262-015-1660-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
54 Sasada T, Kibe S, Akagi Y, Itoh K. Personalized peptide vaccination for advanced colorectal cancer. Oncoimmunology 2015;4:e1005512. [PMID: 26155407 DOI: 10.1080/2162402X.2015.1005512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
55 Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics 2015;14:658-73. [PMID: 25576301 DOI: 10.1074/mcp.M114.042812] [Cited by in Crossref: 299] [Cited by in F6Publishing: 303] [Article Influence: 37.4] [Reference Citation Analysis]
56 Liu X, Kline J. Selection and Monitoring of Patients for Immunotherapy (Peptide Vaccines). Immunopharmacogenomics 2015. [DOI: 10.1007/978-4-431-55726-5_4] [Reference Citation Analysis]
57 Toh U, Sasada T, Takahashi R, Itoh K, Akagi Y. Tumor Immunotherapy of Esophageal and Gastric Cancers. Cancer Immunology 2015. [DOI: 10.1007/978-3-662-46410-6_9] [Reference Citation Analysis]
58 Uhlig T, Kyprianou T, Martinelli FG, Oppici CA, Heiligers D, Hills D, Calvo XR, Verhaert P. The emergence of peptides in the pharmaceutical business: From exploration to exploitation. EuPA Open Proteomics 2014;4:58-69. [DOI: 10.1016/j.euprot.2014.05.003] [Cited by in Crossref: 304] [Cited by in F6Publishing: 182] [Article Influence: 33.8] [Reference Citation Analysis]
59 Zhou J. Advances and Prospects in Cancer Immunotherapy. New Journal of Science 2014;2014:1-13. [DOI: 10.1155/2014/745808] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
60 Lee DH. Cancer Immunotherapy: The Dawn of the Renaissance after the Medieval Dark Ages. Korean J Med 2014;87:284. [DOI: 10.3904/kjm.2014.87.3.284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Talebian Yazdi M, Keene KR, Hiemstra PS, van der Burg SH. Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. Expert Rev Vaccines 2014;13:87-116. [PMID: 24308580 DOI: 10.1586/14760584.2014.862499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 Suzuki H, Owada Y, Watanabe Y, Inoue T, Fukuharav M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Ohsugi J, Hoshino M, Higuchi M, Shio Y, Gotoh M. Recent advances in immunotherapy for non-small-cell lung cancer. Hum Vaccin Immunother 2014;10:352-7. [PMID: 24196313 DOI: 10.4161/hv.26919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
63 Yutani S, Komatsu N, Matsueda S, Yoshitomi M, Shirahama T, Yamada A, Itoh K, Sasada T. Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine. Evid Based Complement Alternat Med 2013;2013:981717. [PMID: 23840274 DOI: 10.1155/2013/981717] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
64 Takahashi R, Yoshitomi M, Yutani S, Shirahama T, Noguchi M, Yamada A, Itoh K, Sasada T. Current status of immunotherapy for the treatment of biliary tract cancer. Hum Vaccin Immunother. 2013;9:1069-1072. [PMID: 23376808 DOI: 10.4161/hv.23844] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]